• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

川崎病和中毒性休克综合征后的先天性免疫反应。

Innate immune responses following Kawasaki disease and toxic shock syndrome.

作者信息

Chen Katherine Y H, Messina Nicole, Germano Susie, Bonnici Rhian, Freyne Bridget, Cheung Michael, Goldsmith Greta, Kollmann Tobias R, Levin Michael, Burgner David, Curtis Nigel

机构信息

Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Vic, Australia.

Department of Paediatrics, The University of Melbourne, Melbourne, Vic, Australia.

出版信息

PLoS One. 2018 Feb 15;13(2):e0191830. doi: 10.1371/journal.pone.0191830. eCollection 2018.

DOI:10.1371/journal.pone.0191830
PMID:29447181
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5813928/
Abstract

The pathogenesis of Kawasaki disease (KD) remains unknown and there is accumulating evidence for the importance of the innate immune system in initiating and mediating the host inflammatory response. We compared innate immune responses in KD and toxic shock syndrome (TSS) participants more than two years after their acute illness with control participants to investigate differences in their immune phenotype. Toxic shock syndrome shares many clinical features with KD; by including both disease groups we endeavoured to explore changes in innate immune responses following acute inflammatory illnesses more broadly. We measured the in vitro production of interferon (IFN)-γ, tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-1 receptor antagonist (IL-1ra), and IL-10 following whole blood stimulation with toll-like receptor and inflammasome ligands in 52 KD, 20 TSS, and 53 control participants in a case-control study. Analyses were adjusted for age, sex, and unstimulated cytokine concentrations. Compared to controls, KD participants have reduced IL-1ra production in response to stimulation with double stranded RNA (geometric mean ratio (GMR) 0.37, 95% CI 0.15, 0.89, p = 0.03) and increased IL-6 production in response to incubation with Lyovec™ (GMR 5.48, 95% CI 1.77, 16.98, p = 0.004). Compared to controls, TSS participants have increased IFN-γ production in response to peptidoglycan (GMR 4.07, 95% CI 1.82, 9.11, p = 0.001), increased IL-1β production to lipopolysaccharide (GMR 1.64, 95% CI 1.13, 2.38, p = 0.01) and peptidoglycan (GMR 1.61, 95% CI 1.11, 2.33, p = 0.01), and increased IL-6 production to peptidoglycan (GMR 1.45, 95% CI 1.10, 1.92, p = 0.01). Years following the acute illness, individuals with previous KD or TSS exhibit a pro-inflammatory innate immune phenotype suggesting a possible underlying immunological susceptibility or innate immune memory.

摘要

川崎病(KD)的发病机制尚不清楚,越来越多的证据表明先天性免疫系统在启动和介导宿主炎症反应中具有重要作用。我们比较了KD和中毒性休克综合征(TSS)患者在急性疾病发生两年多后的先天性免疫反应与对照参与者,以研究他们免疫表型的差异。中毒性休克综合征与KD有许多共同的临床特征;通过纳入这两个疾病组,我们试图更广泛地探索急性炎症性疾病后先天性免疫反应的变化。在一项病例对照研究中,我们测量了52名KD患者、20名TSS患者和53名对照参与者在用Toll样受体和炎性小体配体刺激全血后体外产生的干扰素(IFN)-γ、肿瘤坏死因子(TNF)-α、白细胞介素(IL)-1β、IL-6、IL-1受体拮抗剂(IL-ira)和IL-10。分析对年龄、性别和未刺激的细胞因子浓度进行了校正。与对照组相比,KD患者对双链RNA刺激的IL-ira产生减少(几何平均比(GMR)0.37,95%可信区间0.15,0.89,p = 0.03),对Lyovec™孵育的IL-6产生增加(GMR 5.48,95%可信区间1.77,16.98,p = 0.004)。与对照组相比,TSS患者对肽聚糖的IFN-γ产生增加(GMR 4.07,95%可信区间1.82,9.11,p = 0.001),对脂多糖的IL-1β产生增加(GMR 1.64,95%可信区间1.13,2.38,p = 0.01)和对肽聚糖的IL-1β产生增加(GMR 1.61,95%可信区间1.11,2.33,p = 0.01),对肽聚糖的IL-6产生增加(GMR 1.45,95%可信区间1.10,1.92,p = 0.01)。在急性疾病发生数年之后,既往患有KD或TSS的个体表现出促炎的先天性免疫表型,提示可能存在潜在的免疫易感性或先天性免疫记忆。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5341/5813928/6aa6091d3974/pone.0191830.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5341/5813928/6df524218006/pone.0191830.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5341/5813928/3ba0c6c89e2b/pone.0191830.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5341/5813928/6aa6091d3974/pone.0191830.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5341/5813928/6df524218006/pone.0191830.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5341/5813928/3ba0c6c89e2b/pone.0191830.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5341/5813928/6aa6091d3974/pone.0191830.g003.jpg

相似文献

1
Innate immune responses following Kawasaki disease and toxic shock syndrome.川崎病和中毒性休克综合征后的先天性免疫反应。
PLoS One. 2018 Feb 15;13(2):e0191830. doi: 10.1371/journal.pone.0191830. eCollection 2018.
2
[Changes and significance for regulatory factors for signal pathways of Toll-like receptors in immunological pathogenesis of Kawasaki disease].[川崎病免疫发病机制中Toll样受体信号通路调节因子的变化及意义]
Zhonghua Er Ke Za Zhi. 2008 Jan;46(1):49-54.
3
Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.抗肿瘤坏死因子治疗失败的溃疡性结肠炎患者的固有免疫失调。
World J Gastroenterol. 2016 Nov 7;22(41):9104-9116. doi: 10.3748/wjg.v22.i41.9104.
4
[The role of activation of toll-like receptors in immunological pathogenesis of Kawasaki disease].[Toll样受体激活在川崎病免疫发病机制中的作用]
Zhonghua Er Ke Za Zhi. 2006 May;44(5):333-6.
5
Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.川崎病患儿 NKG2D 表达水平异常降低。
Scand J Immunol. 2013 May;77(5):389-97. doi: 10.1111/sji.12022.
6
IL-1β triggered by peptidoglycan and lipopolysaccharide through TLR2/4 and ROS-NLRP3 inflammasome-dependent pathways is involved in ocular Behçet's disease.由肽聚糖和脂多糖通过 TLR2/4 和 ROS-NLRP3 炎性小体依赖性途径触发的 IL-1β 参与了眼部贝赫切特病。
Invest Ophthalmol Vis Sci. 2013 Jan 14;54(1):402-14. doi: 10.1167/iovs.12-11047.
7
The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.TLR7/TLR8 和 TLR9 配体可恢复皮肤扁平苔藓中由 Toll 样受体激活引发的功能失调的固有免疫反应。
Br J Dermatol. 2015 Jan;172(1):48-55. doi: 10.1111/bjd.13214. Epub 2014 Nov 20.
8
High levels of circulating interleukin-4 and interleukin-10 in Kawasaki disease.川崎病中循环白细胞介素-4和白细胞介素-10水平升高。
Int Arch Allergy Immunol. 1997 Feb;112(2):152-6. doi: 10.1159/000237447.
9
[Kawasaki disease and innate immunity].[川崎病与固有免疫]
Nihon Rinsho. 2014 Sep;72(9):1542-7.
10
Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses.丝裂原活化蛋白激酶磷酸酶1(MKP-1)在天然免疫反应中对促炎和抗炎细胞因子的动态调节
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2274-9. doi: 10.1073/pnas.0510965103. Epub 2006 Feb 6.

引用本文的文献

1
Pyroptosis in Kawasaki disease: from mechanisms to targeted interventions.川崎病中的细胞焦亡:从机制到靶向干预
Front Immunol. 2025 Apr 16;16:1566985. doi: 10.3389/fimmu.2025.1566985. eCollection 2025.
2
Association between gene polymorphisms and coronary artery lesion in Kawasaki disease.川崎病基因多态性与冠状动脉病变的相关性
Front Med (Lausanne). 2023 Jul 27;10:1193303. doi: 10.3389/fmed.2023.1193303. eCollection 2023.
3
Identifying differentially expressed genes and miRNAs in Kawasaki disease by bioinformatics analysis.

本文引用的文献

1
Identifying genetic hypomethylation and upregulation of Toll-like receptors in Kawasaki disease.川崎病中Toll样受体的基因低甲基化及上调的鉴定
Oncotarget. 2017 Feb 14;8(7):11249-11258. doi: 10.18632/oncotarget.14497.
2
Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.综述:殊途同归:针对川崎病治疗的白细胞介素-1 阻断的国际研究进展
Arthritis Rheumatol. 2017 Feb;69(2):268-276. doi: 10.1002/art.39975.
3
Inositol-Triphosphate 3-Kinase C Mediates Inflammasome Activation and Treatment Response in Kawasaki Disease.
通过生物信息学分析鉴定川崎病差异表达的基因和 miRNA。
Sci Rep. 2022 Dec 19;12(1):21879. doi: 10.1038/s41598-022-26608-x.
4
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First-in-Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose).口服 NLRP3 炎性小体抑制剂 ZYIL1 的安全性、耐受性、药代动力学和药效学:首次人体 I 期研究(单次递增剂量和多次递增剂量)。
Clin Pharmacol Drug Dev. 2023 Feb;12(2):202-211. doi: 10.1002/cpdd.1162. Epub 2022 Sep 5.
5
Correlation Between Matrix Metalloproteinases With Coronary Artery Lesion Caused by Kawasaki Disease.基质金属蛋白酶与川崎病所致冠状动脉病变的相关性
Front Pediatr. 2022 Feb 11;10:802217. doi: 10.3389/fped.2022.802217. eCollection 2022.
6
Complement 3 and the Prognostic Nutritional Index Distinguish Kawasaki Disease from Other Fever Illness with a Nomogram.补体3与预后营养指数通过列线图鉴别川崎病与其他发热性疾病。
Children (Basel). 2021 Sep 20;8(9):825. doi: 10.3390/children8090825.
7
Innate immune response analysis in COVID-19 and kawasaki disease reveals MIS-C predictors.COVID-19 和川崎病的先天免疫反应分析揭示了 MIS-C 的预测因子。
J Formos Med Assoc. 2022 Mar;121(3):623-632. doi: 10.1016/j.jfma.2021.06.009. Epub 2021 Jun 19.
8
Aetiological Significance of Infectious Stimuli in Kawasaki Disease.川崎病中感染性刺激的病因学意义
Front Pediatr. 2019 Jun 28;7:244. doi: 10.3389/fped.2019.00244. eCollection 2019.
9
The Gene Polymorphisms rs16944 and rs1143627 Contribute to an Increased Risk of Coronary Artery Lesions in Southern Chinese Children with Kawasaki Disease.基因多态性 rs16944 和 rs1143627 增加了中国南方川崎病患儿冠状动脉损伤的风险。
J Immunol Res. 2019 Apr 9;2019:4730507. doi: 10.1155/2019/4730507. eCollection 2019.
10
Incomplete Refractory Kawasaki Disease in an Infant-A Case Report and a Review of the Literature.婴儿不完全性难治性川崎病——病例报告及文献综述
Front Pediatr. 2018 Jul 27;6:210. doi: 10.3389/fped.2018.00210. eCollection 2018.
肌醇三磷酸3激酶C介导川崎病中的炎性小体激活及治疗反应
J Immunol. 2016 Nov 1;197(9):3481-3489. doi: 10.4049/jimmunol.1600388. Epub 2016 Sep 30.
4
Kawasaki disease: a matter of innate immunity.川崎病:先天性免疫问题。
Clin Exp Immunol. 2016 Nov;186(2):134-143. doi: 10.1111/cei.12832. Epub 2016 Aug 3.
5
Inflammasomes: mechanism of assembly, regulation and signalling.炎症小体:组装、调控和信号转导机制。
Nat Rev Immunol. 2016 Jul;16(7):407-20. doi: 10.1038/nri.2016.58. Epub 2016 Jun 13.
6
Trained immunity: A program of innate immune memory in health and disease.训练有素的免疫:健康与疾病中的固有免疫记忆程序。
Science. 2016 Apr 22;352(6284):aaf1098. doi: 10.1126/science.aaf1098. Epub 2016 Apr 21.
7
Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).阿那白滞素用于川崎病合并早期冠状动脉异常患儿的I/IIa期试验的原理与研究设计(ANAKID试验)
Contemp Clin Trials. 2016 May;48:70-5. doi: 10.1016/j.cct.2016.04.002. Epub 2016 Apr 11.
8
Kawasaki Disease.川崎病。
J Am Coll Cardiol. 2016 Apr 12;67(14):1738-49. doi: 10.1016/j.jacc.2015.12.073.
9
Variations in ORAI1 Gene Associated with Kawasaki Disease.与川崎病相关的ORAI1基因变异
PLoS One. 2016 Jan 20;11(1):e0145486. doi: 10.1371/journal.pone.0145486. eCollection 2016.
10
Molecular mechanisms regulating NLRP3 inflammasome activation.调节NLRP3炎性小体激活的分子机制。
Cell Mol Immunol. 2016 Mar;13(2):148-59. doi: 10.1038/cmi.2015.95. Epub 2015 Nov 9.